These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24614638)

  • 1. [Pharmacological properties and clinical efficacy of tetrabenazine (Choreazine(®)Tablets 12.5 mg), a therapeutic agent for non-rhythmic involuntary movement].
    Machida K; Kawakami D; Miki M
    Nihon Yakurigaku Zasshi; 2014 Mar; 143(3):144-51. PubMed ID: 24614638
    [No Abstract]   [Full Text] [Related]  

  • 2. Deutetrabenazine for the treatment of Huntington's chorea.
    Bashir H; Jankovic J
    Expert Rev Neurother; 2018 Aug; 18(8):625-631. PubMed ID: 29996061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders.
    Guay DR
    Am J Geriatr Pharmacother; 2010 Aug; 8(4):331-73. PubMed ID: 20869622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deutetrabenazine (Austedo) for Huntington's chorea and tardive dyskinesia.
    Med Lett Drugs Ther; 2018 Apr; 60(1545):65-68. PubMed ID: 29667946
    [No Abstract]   [Full Text] [Related]  

  • 5. Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease.
    Dean M; Sung VW
    Drug Des Devel Ther; 2018; 12():313-319. PubMed ID: 29497277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other?
    Stahl SM
    CNS Spectr; 2018 Aug; 23(4):239-247. PubMed ID: 30160230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deutetrabenazine in the treatment of tardive dyskinesia.
    Niemann N; Jimenez-Shahed J
    Neurodegener Dis Manag; 2019 Apr; 9(2):59-71. PubMed ID: 30702019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deuterated drugs draw heavier backing.
    Mullard A
    Nat Rev Drug Discov; 2016 Apr; 15(4):219-21. PubMed ID: 27032821
    [No Abstract]   [Full Text] [Related]  

  • 9. Identification of conformationally sensitive residues essential for inhibition of vesicular monoamine transport by the noncompetitive inhibitor tetrabenazine.
    Ugolev Y; Segal T; Yaffe D; Gros Y; Schuldiner S
    J Biol Chem; 2013 Nov; 288(45):32160-32171. PubMed ID: 24062308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deuterium Tetrabenazine for Tardive Dyskinesia.
    Cummings MA; Proctor GJ; Stahl SM
    Clin Schizophr Relat Psychoses; 2018 Jan; 11(4):214-220. PubMed ID: 29341821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single Dose and Repeat Once-Daily Dose Safety, Tolerability and Pharmacokinetics of Valbenazine in Healthy Male Subjects.
    Luo R; Bozigian H; Jimenez R; Loewen G; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):44-52. PubMed ID: 28839339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene therapy offers HD patients relief from some symptoms. Tetrabenazine inhibits the transport of a molecule called vesicular monoamine transporter type 2 or VMAT2.
    Morrow T
    Manag Care; 2008 Nov; 17(11):46-7. PubMed ID: 19052001
    [No Abstract]   [Full Text] [Related]  

  • 13. Tardive Syndrome Associated With Tetrabenazine in Huntington Disease: A Case Report.
    Palermo G; Mazzucchi S; Unti E; Bonuccelli U; Ceravolo R
    J Clin Psychopharmacol; 2020; 40(6):628-630. PubMed ID: 33136925
    [No Abstract]   [Full Text] [Related]  

  • 14. Deutetrabenazine in the treatment of Huntington's disease.
    Richard A; Frank S
    Neurodegener Dis Manag; 2019 Feb; 9(1):31-37. PubMed ID: 30624137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetrabenazine (Xenazine) for Huntington's chorea.
    Med Lett Drugs Ther; 2009 Jan; 51(1304):7-8. PubMed ID: 19172140
    [No Abstract]   [Full Text] [Related]  

  • 16. Tetrabenazine in the treatment of hyperkinetic movement disorders.
    Kenney C; Jankovic J
    Expert Rev Neurother; 2006 Jan; 6(1):7-17. PubMed ID: 16466307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review.
    Caroff SN; Aggarwal S; Yonan C
    J Comp Eff Res; 2018 Feb; 7(2):135-148. PubMed ID: 28965423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The vesicular monoamine transporter (VMAT-2) inhibitor tetrabenazine induces tremulous jaw movements in rodents: implications for pharmacological models of parkinsonian tremor.
    Podurgiel SJ; Nunes EJ; Yohn SE; Barber J; Thompson A; Milligan M; Lee CA; López-Cruz L; Pardo M; Valverde O; Lendent C; Baqi Y; Müller CE; Correa M; Salamone JD
    Neuroscience; 2013 Oct; 250():507-19. PubMed ID: 23867769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tetrabenazine (tetrabenazine Orphan) orally].
    J Pharm Belg; 2014 Dec; (4):49-50. PubMed ID: 25562927
    [No Abstract]   [Full Text] [Related]  

  • 20. VMAT2 Inhibitors for Tardive Dyskinesia-Practice Implications.
    Peckham AM; Nicewonder JA
    J Pharm Pract; 2019 Aug; 32(4):450-457. PubMed ID: 29455579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.